Related Experiment Video
Updated: Jun 6, 2025
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised
Sunil V Badve1, Anika Bilal2, Matthew M Y Lee3
1St George Hospital, Sydney, NSW, Australia; Renal and Metabolic Division, The George Institute for Global Health, Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia.
Insights
Glucagon-like peptide-1 (GLP-1) receptor agonists significantly reduce kidney events and major adverse cardiovascular events (MACE) in patients with type 2 diabetes. These findings highlight the dual benefits of GLP-1 receptor agonists for cardiovascular and kidney health.
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Glucagon-like peptide-1 (GLP-1) receptor agonists are known to reduce major adverse cardiovascular events (MACE) and offer potential kidney benefits.
- However, definitive evidence on their impact on clinically significant kidney outcomes remains uncertain.
Purpose of the Study:
- To conduct a comprehensive meta-analysis of randomized controlled trials to assess the effects of GLP-1 receptor agonists on both kidney and cardiovascular disease outcomes.
- To clarify the role of GLP-1 receptor agonists in preventing kidney-related complications.
Main Methods:
- A systematic search of MEDLINE, Embase, and Cochrane Central Register of Controlled Trials was performed for randomized controlled trials.
- Included trials involved at least 500 participants with type 2 diabetes, compared GLP-1 receptor agonists with placebo, had a follow-up of at least 12 months, and reported primary kidney or cardiovascular outcomes.
- The SELECT trial, including participants with cardiovascular disease and obesity, was also included post hoc.
Main Results:
- The meta-analysis included 11 trials with 85,373 participants. GLP-1 receptor agonists significantly reduced the composite kidney outcome by 18% (HR 0·82) and kidney failure by 16% (HR 0·84) in patients with type 2 diabetes.
- Major adverse cardiovascular events (MACE) were reduced by 13% (HR 0·87) and all-cause death by 12% (HR 0·88).
- No significant difference in serious adverse events like pancreatitis or hypoglycemia was observed, though treatment discontinuation due to adverse events was more frequent.
Conclusions:
- GLP-1 receptor agonists demonstrate significant efficacy in reducing clinically important kidney events and kidney failure.
- The findings provide strong evidence for the dual benefit of GLP-1 receptor agonists in managing both cardiovascular and kidney disease progression.
Background:
GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) and can also have kidney benefits. However, whether GLP-1 receptor agonists improve clinically important kidney outcomes remains uncertain. We aimed to comprehensively assess the effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes by performing a meta-analysis of randomised controlled trials.
Methods:
For this meta-analysis, we searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for randomised controlled trials that included at least 500 participants with type 2 diabetes, compared a GLP-1 receptor agonist with placebo with at least 12 months of follow-up, and reported a primary clinical kidney or cardiovascular outcome, from database inception to March 26, 2024. Post hoc, we included the SELECT trial (NCT03574597), which enrolled participants with cardiovascular disease and a BMI of 27 kg/m2 or more without diabetes. Study-level summary data were extracted independently by two authors for inclusion in this random-effects analysis. The main kidney outcome was a composite outcome, consisting of kidney failure (kidney replacement therapy or a persistent estimated glomerular filtration rate [eGFR] <15 mL/min per 1·73 m2), a sustained reduction in eGFR by at least 50% or the nearest equivalent, or death from kidney failure. The main cardiovascular outcome was MACE, consisting of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. This study is registered with PROSPERO, CRD42024528864.
Findings:
Of the 5140 records identified through the literature search, 11 trials, involving 85 373 participants (29 386 female, 55 987 male), were included in the meta-analysis. In participants with type 2 diabetes (67 769), GLP-1 receptor agonists reduced the composite kidney outcome by 18% compared with placebo (hazard ratio [HR] 0·82, 95% CI 0·73-0·93; I2 =26·41%), kidney failure by 16% (HR 0·84, 0·72-0·99; I2 =0%), MACE by 13% (HR 0·87, 0·81-0·93; I2 =49·75%), and all-cause death by 12% (HR 0·88, 0·83-0·93; I2 =0%). The effect on the composite kidney outcome (HR 0·81, 95% CI 0·72-0·92; I2 =23·11%), kidney failure (HR 0·84, 0·72-0·98; I2 =0%), MACE (HR 0·86, 0·80-0·92; I2 =48·9%), and all-cause death (HR 0·87, 0·82-0·91; I2 =0%) was similar when the SELECT trial was included, with no evidence of heterogeneity between this trial and those including participants with type 2 diabetes (pheterogeneity >0·05). There was no difference in the risk of serious adverse events, including acute pancreatitis and severe hypoglycaemia, between the GLP-1 receptor agonist and placebo groups (risk ratio [RR] 0·95, 95% CI 0·90-1·01; I2 =88·5%). However, treatment discontinuation due to adverse events occurred more frequently in the GLP-1 receptor agonist groups (RR 1·51, 95% CI 1·18-1·94; I2 =96·3%).
Interpretation:
We found evidence that GLP-1 receptor agonists significantly reduce clinically important kidney events, kidney failure, and cardiovascular events.
Funding:
None.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:23Dipeptidyl Peptidase 4 Inhibitors
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
01:06Oral Hypoglycemic Agents: Glinides
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System